医学
梅德林
医学物理学
肿瘤科
重症监护医学
内科学
法学
政治学
作者
Ken K. Y. Ho,Maria Fleseriu,John Wass,Laurence Katznelson,Gérald Raverot,Andrew S. Little,Justo P. Castaño,Martín Reincke,M. Beatriz S. Lopes,Ursula B. Kaiser,Philippe Chanson,Mônica R. Gadelha,Shlomo Melmed
标识
DOI:10.1016/s2213-8587(23)00382-0
摘要
No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.
科研通智能强力驱动
Strongly Powered by AbleSci AI